Sort
39,280 grants matching “leukemia”
Humanized bone marrow-like model to study patient-derived myeloma xenografts
$563,030Constantine S. Mitsiades · Dana-Farber Cancer Inst · R01 · FY2016 · CA
Defining the partner interaction network of the tetraspanin CD53 in regulating B cell trafficking
$563,006Laura G. Schuettpelz · Washington University · R01 · FY2024 · AI
XBP1 Inhibition and STING activation for the treatment of cancer
$562,994Chih-Chi Andrew Hu · Methodist Hospital Research Institute · R01 · FY2023 · CA
Health Literacy Assessment and Intervention to Reduce Disparities: FLIGHT/VIDAS II
$562,926Raymond L Ownby · Nova Southeastern University · R01 · FY2017 · MD
Preventing GVHD by inhibition of alloantigen presentation in the gut
$562,863Geoffrey Roger Hill · Fred Hutchinson Cancer Research Center · R01 · FY2021 · HL
Phase 1 Evaluation of Enhanced Natural Killer Cells as a Treatment Strategy in Non-Small cell Lung Cancer Patients Refractory to PD-1/PD-L1 Immune Checkpoint Inhibitors
$562,792Miguel Angel Villalona · University Of California-Irvine · R01 · FY2025 · CA
Western Regional Community Clinical Oncology Program
$562,644Banner Good Samaritan Medical Center · U10 · FY2004 · CA
Molecular Epidemiology of NHL and CLL
$562,598James R Cerhan · Mayo Clinic Rochester · R01 · FY2012 · CA
Project 2: Molecular Modulation of Chromatin and Nuclear Structure in Cancer
$562,587Jonathan D. Licht · Northwestern University At Chicago · U54 · FY2017 · CA
Modeling Tyrosine Kinase Inhibitor-Induced Vascular Dysfunction Using Human iPSCs
$562,562Joseph C Wu · Stanford University · R01 · FY2021 · HL
Defining the partner interaction network of the tetraspanin CD53 in regulating B cell trafficking
$562,543Laura G. Schuettpelz · Washington University · R01 · FY2025 · AI
The Characterization of RNA Binding Motif Protein 48 (RBM48) in U12 Intron Splicing, Cellular Differentiation, and Development
$562,500Shailesh Lal · Oakland University · R15 · FY2025 · GM
ROS-targeted therapy for pancreatic cancer
$562,471Nouri Neamati · University Of Michigan At Ann Arbor · R01 · FY2017 · CA
ROS-targeted therapy for pancreatic cancer
$562,471Nouri Neamati · University Of Michigan At Ann Arbor · R01 · FY2020 · CA
PROCESSED ANTIGEN CHARACTERIZATION BY MASS SPECTROMETRY
$562,412University Of Virginia Charlottesville · R37 · FY2003 · AI
Transcription Factor Induced Reprogramming
$562,327Konrad Hochedlinger · Massachusetts General Hospital · R01 · FY2019 · HD
Transcription Factor Induced Reprogramming
$562,327Konrad Hochedlinger · Massachusetts General Hospital · R01 · FY2015 · HD
Transcription Factor Induced Reprogramming
$562,327Konrad Hochedlinger · Massachusetts General Hospital · R01 · FY2017 · HD
Molecular Control of Plasmacytoid Dendritic Cell Development and Function
$562,242Boris Reizis · New York University School Of Medicine · R37 · FY2021 · AI
Elucidation of Human Natural Killer Cell Development
$562,208Aharon G Freud · Ohio State University · R01 · FY2025 · CA
Mechanisms and functions of N6-methyladenosine (m6A) in cancer
$562,086Samie R Jaffrey · Weill Medical Coll Of Cornell Univ · R01 · FY2021 · CA
The role and therapeutic potential of IGF2BP2 in MLL-rearranged leukemia
$562,052Jianjun Chen · Beckman Research Institute/City Of Hope · R01 · FY2023 · CA
Gene expression in mature neutrophils
$562,035Univ Of Massachusetts Med Sch Worcester · R01 · FY2004 · DK
Genomics of Megakaryocyte and Platelet Biology
$561,860Jorge A Dipaola · Washington University · R01 · FY2022 · HL
Genomics of Megakaryocyte and Platelet Biology
$561,860Jorge A Dipaola · Washington University · R01 · FY2021 · HL